Agenda
The Asia Partnership Conference of Regenerative Medicine (APACRM), is aimed at harmonizing and optimizing regulations among Asian countries and regions. FIRM has organized APACRM, an annual conference, since 2018, and has closely collaborated with industrial groups such as the China Medicinal Biotech Association (CMBA) in China, Association of Biotechnology Led Enterprises (ABLE) in India, Council for Advanced Regenerative Medicine (CARM) and Strategic Center for Regenerative Medicine (SCRM) in Korea, Singapore Association of Pharmaceuticals Industries (SAPI) in Singapore, and Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) in Taiwan.

The latest APACRM focused on dialog with regulators based on survey results from three working groups: non-clinical, quality assessments, and environmental impact assessment settings for cell and gene therapy products (CGTs). Through panel discussions comprised of major Asian regulatory agencies, regulation differences and their underlying rationales have been more clearly defined among the participating countries and regions. The hope is that an environment of harmonization is cultivated by sharing experiences regarding products under development, and opinions on regulatory guidelines. Moreover, more proactive efforts on regulatory innovation (e.g., the necessity of new guidelines) regarding regenerative medicinal products can assist with regulatory harmonization and optimization across Asia. This would enable the rapid delivery of CGTs to more patients, thus achieving market maximization of CGTs throughout Asia. This session will explore prospects and challenges to promote harmonization and optimization of regulations on regenerative medicine products among Asian countries and regions.

Chair: Masa yuki (Max) Nomura, Ph.D., Chair, International Affairs Committee, Forum for Innovative Regenerative Medicine (FIRM)

Speakers:
- Ryan Chang, Advisor, Acepodia
- Hiroshi Karasawa, Ph.D., Scientist, Cell Therapy Research Laboratories, Daiichi Sankyo
- Masaaki Miyano, Manager, CMC Regulatory Affairs Department, Chugai Pharmaceutical
- Masahiko Yasumoto, Executive Officer, Deputy Division Director, R&D Division, NanoCarrier

PRE-RECORDED VIRTUAL COMPANY PRESENTATIONS
- Advarra
- ATMPS
- Avectas
- AVROBIO
- Cellusion
- Century Therapeutics
- DiscGenics
- Gamida Cell
- Kytopen
- Myrtelle
- Qurgen
- Talaris

IN-PERSON PROGRAM AND LIVESTREAM

REGISTRATION AND BREAKFAST Sponsored by KBI Biopharma

WHAT’S NEXT FOR CELL AND GENE THERAPIES IN 2023 AND BEYOND WORKSHOP
Sponsored by Precision ADVANCE
Oxford Biomedica Ballroom

This workshop will feature leading executives in the ATMP space who will discuss a number of topics including future technologies, the current investment environment and what innovators can do to mitigate growing market pressures. The session will also touch upon resolving manufacturing and regulatory bottlenecks as the sector moves towards commercialization, as well as the evolution of reimbursement payment models.

Chair: Anshul Mangal, President, Precision ADVANCE and Project Farma

Speakers:
- Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone Biologics
- Andrew Knudten, Chief Operating Officer, Jaguar Gene Therapy
- Laura Lande-Diner, Ph.D., Chief Business Officer, Satellite Bio
HOW INDUSTRY 4.0 PRINCIPLES WILL HELP DRIVE THE ADOPTION OF ADVANCED CELL THERAPIES WORKSHOP
Sponsored by Gamma Biosciences
Aviara Salon A

The industry has come this far highly dependent on technologies and lessons learned from the biologics industry. How are those habits helping and hurting the progress of cell and gene therapy manufacturing? How can emerging concepts of continuous biomanufacturing, process analytical technologies (PAT), and automation help us rethink manufacturing strategies today, and for years to come? Learn from a panel of experts and industry veterans what the future will look like in advanced therapy manufacturing.

Chair: Phil Vanek, Ph.D., Chief Technology Officer and Partner, Gamma Biosciences

Speakers:
- Andy Lin, Ph.D., Vice President and Global Head of Individualized and Cell Therapy Development, Genentech
- Damian Marshall, Ph.D., Vice President, Analytical Development, Resolution Therapeutics
- Michael May, Ph.D., President and CEO, CCRM
- Alison Moore, Ph.D., Chief Technical Officer, Allogene Therapeutics

SECRETS OF SCALE: HOW THE CONVERGENCE OF SYSTEMS BIOLOGY, ENGINEERING AND NON-CONVENTIONAL REGULATORY APPROACHES ACCELERATE CELL-BASED THERAPIES TO MARKET WORKSHOP
Sponsored by Advanced Regenerative Manufacturing Institute (ARMI)
Aviara Salon B

This workshop will discuss breaking down historical barriers to scalable, consistent, cost-effective manufacturing of cell-based therapies by exploiting the convergence of systems biology, advanced process technology development, and non-conventional regulatory approaches.

Chair: Richard McFarland, M.D., Ph.D., Chief Regulatory Officer, Advanced Regenerative Manufacturing Institute (ARMI)

Speakers:
- Carter Cliff, Co-Founder and CEO, Vascugen
- Esther Latres, Ph.D., Assistant Vice President of Research, JDRF International
- Lloyd Rose, Ph.D., Product Manager, Warfighter Expeditionary Medicine and Treatment, U.S. Army Medical Materiel Development Activity; Program Manager, BioFabUSA

9:00 am GENERAL SESSION AND PARTNERING OPENS

9:00 am

WELCOME REMARKS
UBC Ballroom

Speakers:
- Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)
- Emile Nuwaysir, Ph.D., CEO, Ensoma; Chairman, Alliance for Regenerative Medicine (ARM)

9:15 – 10:15 am CONCURRENT TRACKS

9:15 am

PLENARY SESSION: CURRENT TRENDS AND CHALLENGES SURROUNDING GENE THERAPY COMMERCIALIZATION
UBC Ballroom

With more and more gene therapies expected to be approved by health authorities in the coming years, we must now turn to the next major hurdle in bringing these transformative medicines to patients: commercialization. Beyond addressing the elephant in the room – price – companies must navigate early access, accelerated approval requirements, novel go-to-market challenges, and considerations of global equity, while managing the intersection of highly engaged and often demanding patient communities, physicians, payors, and governments. Hear from how the emerging leaders in this space are coping with these challenges to deliver on the promises of advanced therapies.

COMPANY PRESENTATIONS
Oxford Biomedica Ballroom

9:15 am Aspen Neuroscience
9:30 am BioCentriq
9:45 am Encoded Therapeutics
10:00 am BlueRock Therapeutics
10:15 – 10:45 am MORNING BREAK
Sponsored by Accelerated Biosciences, Exothera, Minaris Regenerative Medicine and Triangle Insights Group

10:45 am – 12:15 pm CONCURRENT TRACKS

10:45 am EVALUATING THE QUALITY OF TISSUE ENGINEERED PRODUCTS
UBC Ballroom
Tissue engineered products, which are complex living structures, have unique considerations with respect to characterization and release testing. This expert panel will discuss challenges associated with potency assays, stability testing, and scaling manufacturing.
Chair: Jane Lebkowski, Ph.D., President, Regenerative Patch Technologies
Speakers: Geoff Hamilton, Co-Founder and CEO, Stemson Therapeutics
Kevin Healy, Ph.D., Senior Vice President Regulatory Affairs, Pharmacovigilance, and Quality, Enzyvant Therapeutics
Eric Roos, Chief Business Development Officer, Aspect Biosystems

COMPANY PRESENTATIONS
Oxford Biomedica Ballroom
10:45 am Cabaletta Bio
11:00 am ExCellThera

COMPANY PRESENTATIONS
UBC Ballroom
11:15 am Intellia Therapeutics
11:30 am 4D Molecular Therapeutics
11:45 am Tenaya Therapeutics
12:00 pm PTC Therapeutics

12:15 – 1:15 pm LUNCH Sponsored by Notch Therapeutics

1:15 – 3:30 pm CONCURRENT TRACKS

1:15 pm THE CURRENT STATE OF INVESTMENT IN CELL AND GENE THERAPY
UBC Ballroom
What is the state of investment in cell and gene therapy globally and the outlook for the rest of 2022 and beyond? This panel will discuss the availability and deployment of capital, from the perspective of venture capital, mergers and acquisitions, and contract manufacturing.

COMPANY PRESENTATIONS
Oxford Biomedica Ballroom
1:15 pm CTI
1:30 pm Mission Bio
1:45 pm Sigilon Therapeutics
2:00 pm Ossium Health
Chair: Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer Inc.

Speakers: Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult
Amy DuRoss, President, Cell and Gene Therapies, CSafe Global; Senior Advisor, Frazier Healthcare Partners
Albert Hwang, M.D., Managing Director, Morgan Stanley
Dmitry Kuzmin, Ph.D., Managing Partner, 4BIO Capital
Becky Pferdehirt, Ph.D., Investment Partner, Andreessen Horowitz
Josh Schimmer, M.D., Senior Managing Director, Evercore

COMPANY PRESENTATIONS
UBC Ballroom
2:15 pm uniQure
2:30 pm Rocket Pharmaceuticals
2:45 pm Helixmith
3:00 pm Sernova
3:15 pm Homology Medicines

Chair: Tim Farries, Ph.D., Principal Consultant, Senior Director, Biopharma Excellence

Speakers: Fred Chereau, President and CEO, LogicBio
Albert Seymour, Ph.D., President and CEO, Homology Medicines
Mark Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine
Devyn Smith, Ph.D., CEO, Arbor Biotechnologies

COMPANY PRESENTATIONS
Oxford Biomedica Ballroom
2:15 pm Immusoft
2:30 pm Arbor Biotechnologies
2:45 pm Rejuvenate Bio
3:00 pm WuXi Advanced Therapies
3:15 pm Viralgen Vector Core

3:30 – 4:00 pm AFTERNOON BREAK
Sponsored by Accelerated Biosciences, Exothera, Minaris Regenerative Medicine and Triangle Insights Group

4:00 – 6:00 pm CONCURRENT TRACKS

4:00 pm GENE EDITING ACCELERATES: THE FIRST GENERATION NEARS APPROVAL WHILE NEW APPROACHES PROGRESS THROUGH THE CLINIC
UBC Ballroom
The first-ever approval of a CRISPR gene-editing therapy could be less than a year away, while base editing has already entered the clinic and the first in-vivo CRISPR approaches progress in clinical trials. Panelists will discuss the milestones the sector has recently reached in gene-editing, and forecast the breakthroughs of the near – and longer-term future.

Chair: Tim Farries, Ph.D., Principal Consultant, Senior Director, Biopharma Excellence

Speakers: Fred Chereau, President and CEO, LogicBio
Albert Seymour, Ph.D., President and CEO, Homology Medicines
Mark Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine
Devyn Smith, Ph.D., CEO, Arbor Biotechnologies

COMPANY PRESENTATIONS
Oxford Biomedica Ballroom
4:00 pm Athersys
4:15 pm AffyImmune Therapeutics
4:30 pm Bellicum Pharmaceuticals
4:45 pm Amplo Biotechnology
COMPANY PRESENTATIONS  
UBC Ballroom  
5:00 pm  
Healios K.K.  
5:15 pm  
Precision BioSciences  
5:30 pm  
Senti Biosciences  
5:45 pm  
Arcellx

COMPANY PRESENTATIONS  
Oxford Biomedica Ballroom  
5:00 pm  
NexImmune  
5:15 pm  
In8Bio  
5:30 pm  
Gradalis  
5:45 pm  
Lykan Bioscience

6:00 pm  
PROGRAM AND PARTNERING CLOSES

6:30 – 9:30 pm  
NETWORKING BASH  
Sponsored by BioPharma Excellence by PharmaLex, QbD Vision and ScaleReady
APPROACHES TO IMPLEMENTING AUTOMATION IN CELL THERAPY MANUFACTURING WORKSHOP
Oxford Biomedica Ballroom
Sponsored by Thermo Fisher Scientific

The need for standardization and automation are critical drivers of innovation in cell therapy manufacturing. Implementation of an automated, closed workflow minimizes open processes and manual touchpoints, increases reproducibility, and improves traceability; this has the potential to reduce manufacturing failures and lower COGS thereby facilitating increased patient access. In this workshop, we sit down with industry experts to discuss various approaches to cGMP manufacturing of gene-modified cell therapies at industrial scale.

Chair: Betty Woo, Ph.D., Vice President and General Manager, Cell and Gene Therapy, Thermo Fisher Scientific
Speakers: Dmitry Fradkin, Director, Automation and Systems Development, Kite Pharma
Fred Parietti, Ph.D., Co-Founder and CEO, Multiply Labs
Edwin Stone, Ph.D., Consultant, TTP

THE FUTURE OF CDMO NETWORKS IN CELL AND GENE THERAPY WORKSHOP
Aviara Salon A
Sponsored by IQVIA

This workshop will feature leading executives who will discuss a number of topics surrounding CDMO networks including bottlenecks in personnel capabilities and facilities along with preclinical pipeline driving capacity and workforce requirements. The session will also touch upon downstream requirements such as clinical sites capabilities, data systems, access and diversity, and regulatory bandwidth.

Chair: Amritha Jaishankar, Ph.D., Executive Director, IQVIA Cell and Gene Therapy Translating Center
Speakers: Eytan Abraham, Ph.D., Vice President, Business Head of Cell, Gene and Nucleic Acids Franchises, Resilience
Abla Creasey, Ph.D., Vice President, Therapeutics Development, California Institute for Regenerative Medicine (CIRM)
Haro Hartounian, Ph.D., President and CEO, BioCentriq
Alan Moore, Chief Strategy Officer, Center for Breakthrough Medicines
Nicholas Ostrout, Ph.D., Senior Advisor, Cell and Gene Therapy Corporate Strategy, Charles River Laboratories

ACCELERATING CGTX DISCOVERY AND DEVELOPMENT THROUGH USE OF ADVANCED PHENOTYPIC MODELS AND MACHINE LEARNING TECHNOLOGIES WORKSHOP
Aviara Salon B

This panel will explore the ways in which next-generation engineered in-vitro models can be combined with innovations in machine learning applications to drive more rational development of complex cell and gene therapy products. Leveraging advances in in-vitro model development (ex. engineered iPSC-derived tissues) as a starting point for discovery, AI/ML platforms can help make connections and correlations between cause and effect in CGTx development at a rapid pace, ultimately driving towards faster, cheaper, and more accurate therapeutic outputs. This model is already established in the small molecule space, and this panel will explore how this will translate to the CGTx industry.

Chair: Adam Roose, Vice President, Cell and Gene Commercial Strategy, Adjuvant Partners
Speakers: Isaac Bentwich, M.D., Founder and CEO, Quris Technologies
Robert Deans, Ph.D., Chief Scientific Officer, Synthego
Keith James, Ph.D., Senior Vice President, Drug Discovery, insitro
Emmanouil Metzakopian, Ph.D., Vice President, Research and Development, bit.bio
9:00 am GENERAL SESSION AND PARTNERING OPENS

9:00 – 10:15 am CONCURRENT TRACKS

9:00 am  UPDATE ON ARM'S GROW INTERNSHIP PROGRAM  
UBC Ballroom  
Speaker:  Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)  

9:15 am  PLENARY SESSION: CELL THERAPY COMMERCIALIZATION TODAY AND PREPARING FOR THE FUTURE  
UBC Ballroom  
Over the past several years, the cell therapy industry has seen tremendous progress in bringing new cell therapies to market. Facilitating the delivery of these life-saving therapies and enabling them to address a broader range of indications for larger patient populations requires collaboration and innovation. Panelists will discuss advances in the industry, key challenges and innovative approaches to commercialization, and the value of strategic partnerships that will help drive the future of cell therapies.  
Chair:  Amy Butler, Ph.D., President, Biosciences Division, Thermo Fisher Scientific  
Speakers:  Diana Brainard, M.D., CEO, AlloVir  
Friedrich Graf Finckenstein, M.D., Chief Medical Officer, Iovance Biotherapeutics  
Cintia Piccina, Pharm.D., Chief Commercial Officer, Adaptimmune  
Paul Staich, Vice President and Head of Global Supply Chain, Cell Therapy Operations, Bristol-Myers Squibb  
Pascal Touchon, President and CEO, Atara Biotherapeutics  

COMPANY PRESENTATIONS  
Oxford Biomedica Ballroom  
9:00 am  MilliporeSigma  

10:15 – 10:45 am MORNING BREAK  
Sponsored by Accelerated Biosciences, Exothera, Minaris Regenerative Medicine and Triangle Insights Group  

10:45 am – 12:15 pm CONCURRENT TRACKS

10:45 am  KEYNOTE SPEAKER: TAKING CELL AND GENE THERAPY TO THE NEXT LEVEL  
UBC Ballroom  
Speaker:  Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA)  

11:15 am  OPPORTUNITIES FOR REGULATORY CONVERGENCE IN CELL AND GENE THERAPY  
UBC Ballroom  
Disparate requirements from one country to the next, from preclinical tests to manufacturing, make it difficult for developers to efficiently ensure patients across borders have access to therapies, particularly to rare disease patients whose numbers in any one geography may be very small. Representatives from the US Food and Drug Administration, European Medicines Agency, and Japanese Pharmaceuticals and Medical Devices Agency will discuss areas  

COMPANY PRESENTATIONS  
Oxford Biomedica Ballroom  
10:45 am  Forge Biologics  
9:30 am  ImStem Biotechnology  
9:45 am  Aldevron  
10:00 am  Marken  
11:00 am  Luminary Therapeutics  
11:15 am  Notch Therapeutics  
11:30 am  Prescient Therapeutics  
11:45 am  Curate Biosciences  
12:00 pm  Capricor Therapeutics
where regulators can and are cooperate on common standards, and what next steps are being envisioned to improve equitable access to critical CGT medicines.

**Chair:** Jessie Hanrahan, Ph.D., Chief Regulatory Officer, AavantiBio

**Speakers:**
- Patrick Celis, Ph.D., Lead Scientific Officer, ATMP Office, European Medicines Agency (EMA)
- Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA)
- Yoshiaki Maruyama, Ph.D., Review Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA)

**COMPANY PRESENTATIONS**
- Oxford Biomedica Ballroom
  - 1:15 pm Ray Therapeutics
  - 1:30 pm Coave Therapeutics

**COMPANY PRESENTATIONS**
- Oxford Biomedica Ballroom
  - 1:45 pm Antion Biosciences
  - 2:00 pm Regenerative Patch Technologies
  - 2:15 pm SparingVision
  - 2:30 pm Miltenyi Biomedicine

**COMPANY PRESENTATIONS**
- Oxford Biomedica Ballroom
  - 3:15 pm Almedex
  - 3:30 pm Miromatrix
  - 3:45 pm PBS Biotech
  - 4:00 pm VERIGRAFT
these can assist with pain points such as talent acquisition and retention.

**Chair:** Susan Nichols, Chief Business Officer, ViroCell Biologics

**Speakers:** Eric Blair, Chief Commercial Officer, Andelyn Biosciences

Frédéric Desdouits, Ph.D., CEO, TreeFrog Therapeutics

Behzad Mahdavi, Ph.D., Senior Vice President, Biopharma Manufacturing and Life Sciences Tools, Ginkgo Bioworks

Daniel Smith, Ph.D., Executive Director, Global Cell and Gene Therapy Portfolio, Charles River Laboratories

Arthur Tzianabos, Ph.D., Venture Partner, 5AM Ventures; Chair of the Board, Homology Medicines

---

**COMPANY PRESENTATIONS**

**UBC Ballroom**

4:15 pm Orchard Therapeutics

4:30 pm Atara Biotherapeutics

4:45 pm Autolus

5:00 pm Poseida Therapeutics

5:15 pm Vor Bio

5:30 pm Enzyvant

5:45 pm ImmuneBridge

---

**COMPANY PRESENTATIONS**

**Oxford Biomedica Ballroom**

4:15 pm Cardinal Health

4:30 pm ElevateBio

4:45 pm MaxCyte

5:00 pm Medpace

5:15 pm Terumo BCT

5:30 pm Cryoport Systems

5:45 pm Teknova

---

6:00 pm PROGRAM AND PARTNERING CLOSES
7:00 – 9:00 am  REGISTRATION AND BREAKFAST  
Sponsored by Gift of Life

7:45 – 8:45 am  CONCURRENT WORKSHOPS

7:45 am  
**ADDRESSING THE PRODUCTION NEEDS OF CELL AND GENE THERAPEUTICS: NEW STRATEGIES FOR A CHANGING WORLD WORKSHOP**

*Oxford Biomedica Ballroom*

*Sponsored by SmartLabs*

Join this session to hear experts debate the following industry challenges:

- Austere funding and the financial environment impacting facility development
- Challenges in methods transfer and the effect this has on outsourcing of production
- How complex CMC requirements demand more proprietary and complex QC/QA

**Chair:**  Brian Taylor, Head of Biopharma Solutions, SmartLabs

**Speakers:**  
- Wolfram Carius, Pharm.D., Executive Vice President, Cell and Gene Therapy, Bayer
- Justin Skoble, Ph.D., Vice President of Technical Operations, Caribou Biosciences
- Sarah Yuan, Ph.D., Chief Technical Operations Officer, Sigilon Therapeutics

7:45 am  
**DIGITAL TRANSFORMATION: INTEGRATING AUTOMATED DATA MANAGEMENT SYSTEMS TO ADVANCE CGT MANUFACTURING AND IMPROVE PROCESS CONTROL WORKSHOP**

*Aviara Salon A*

*Sponsored by L7 Informatics*

This workshop discussion will explore ways in which advancements in data capture, data interrogation and analytics will improve advanced therapies product manufacture. Innovations in data processing will help to optimize manufacturing and process development efforts, decreasing associated time and costs. The session will explore how some of the most advanced technology companies are refining and implementing these processes.

**Chair:**  Trent Carrier, Ph.D., Chief Operating Officer, L7 Informatics

**Speakers:**  
- Sammy Datwani, Ph.D., Senior Vice President, Development, Synthego
- Kevin Gordon, Chief Digital Officer, Ori Biotech
- Delara Motlagh, Ph.D., General Manager, Cell Therapy Technologies, Terumo BCT
- Yan Zhang, Ph.D., CEO, Mission Bio

9:00 am  GENERAL SESSION AND PARTNERING OPENS

9:00 – 10:45 am  CONCURRENT TRACKS

9:00 am  
**ARM CLOSING STATEMENTS**

*UBC Ballroom*

**Speaker:**  Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)

9:15 am  
**SPOTLIGHT SESSION: THE PATIENT PERSPECTIVE ON CELL AND GENE THERAPY**

*UBC Ballroom*

**Chair:**  Craig Martin, CEO, Global Genes

**Speaker:**  Aaron Owens, Recessive Dystrophic Epidermolysis Bullosa Patient and Advocate

**COMPANY PRESENTATIONS**

*Oxford Biomedica Ballroom*

9:00 am  
Cook MyoSite

9:15 am  
**COMPANY PRESENTATIONS**

*Oxford Biomedica Ballroom*

9:15 am  
Cynata Therapeutics

9:30 am  
GENETHON
9:45 am

NEW DEVELOPMENTS AND ADVANCEMENTS IN THE WORLD OF PSCS

UBC Ballroom

Chair: Alberto Santagostino, Senior Vice President, Head of Cell and Gene Technologies, Lonza

Speakers: Melissa Carpenter, Ph.D., Chief Scientific Officer, Regenerative Medicine, ElevateBio
Seth Ettenberg, Ph.D., President and CEO, BlueRock Therapeutics
Osvaldo Flores, Ph.D., CEO, Century Therapeutics
Xiaokui Zhang, Ph.D., Chief Scientific Officer, Aspen Neuroscience

10:45 am – 11:00 am

MORNING BREAK

Sponsored by Accelerated Biosciences, Exothera, Minaris Regenerative Medicine and Triangle Insights Group

11:00 am – 12:00 pm

CONCURRENT TRACKS

11:00 am

THE FUTURE OF GENE DELIVERY: IN SEARCH OF GAME-CHANGING IN VIVO APPLICATIONS

UBC Ballroom

Chair: Faraz Ali, CEO, Tenaya Therapeutics

Speakers: Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics
Gary Fortin, Ph.D., Chief Operating Officer, Shape Therapeutics
Philip Johnson, M.D., CEO, Interius Biotherapeutics
Yvette Leung, Head of Corporate Development, Dyno Therapeutics
Emile Nwawasir, Ph.D., President and CEO, Ensoma; Chairman, Alliance for Regenerative Medicine (ARM)

12:00 – 1:00 pm

LUNCH

Sponsored by Theragent

1:00 pm

CONFERENCE CLOSES